by Kuemmerle A, Schmid C, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Ngolo D, Kisala M, and Valverde Mordt O. PLOS NTDs 2020, 14(1): e0008028. doi: 10.1371/journal.pntd.0008028
Summary: A phase IIIb clinical trial to assess the safety, effectiveness, and feasibility of implementation of nifurtimox eflornithine combination therapy for human African trypanosomiasis (HAT) under field conditions in in the Democratic Republic of Congo provided a unique opportunity to examine concomitant drug management. The prescription of concomitant treatments was coherent with the clinical and safety profile of the patients, however, some prescription habits will need to adapt to the evolving pharmacopoeia. The authors propose a list of minimal essential medication that should be available at no cost to patients in treatment wards to help the different actors to plan, manage, and adequately fund drug supplies for patients with advanced HAT infection.
